Abstract
Neovascular age-related macular degeneration (nAMD) can lead to significant vision impairment through the growth of abnormal neovascular membranes in the choroid. Despite advancements with current anti-vascular endothelial growth factor (VEGF) therapies, challenges such as frequent injections, inadequate response, and patient-related concerns persist. Emerging therapeutics aim to reduce vision-loss through a variety of mechanisms. Gene therapies, including RGX-314 and Ixo-vec, express an anti-VEGF protein, and 4D-150, expresses an anti-VEGF protein and a VEGF-C inhibitory miRNA. Anti-VEGF associated therapeutics include OPT-302, targeting VEGF-C and VEGF-D, BI 836880, which inhibits VEGF-A and Ang-2 activity, and Tarcocimab tedromer, inhibiting all VEGF-A isoforms. Agents with novel mechanisms of action include UBX1325, which inhibits an anti-apoptotic protein, Restoret (EYE103), a Wnt agonist, and the tyrosine kinase inhibitors, EYP-1901, OTX-TKI, CLS-AX, and KHK4951.
摘要
新生血管性年龄相关性黄斑变性(nAMD)因脉络膜异常新生血管膜的生长造成严重的视力损害。尽管目前抗血管内皮生长因子 (VEGF) 在治疗方面取得很大进展, 但频繁注射、应答不佳及患者相关问题等挑战依然存在。新兴疗法旨在通过多种作用机制来减少视力丧失。基因治疗包括RGX-314和Ixo-vec表达抗 VEGF 蛋白, 4D-150 表达抗 VEGF 蛋白和抑制 miRNA 的VEGF-C。抗VEGF相关疗法包括针对VEGF-C和VEGF-D的OPT-302, 以及抑制 VEGF-A和Ang-2活性的BI 836880。新的作用机制药物有抑制抗凋亡蛋白Restoret(EYE103)、Wnt激动剂UBX1325以及酪氨酸激酶抑制剂EYP-1901和OTX-TKI。
Similar content being viewed by others
Introduction
Age-related macular degeneration (AMD) poses a significant global health challenge, standing as a leading cause of blindness across many developed nations [1]. Approximately 288 million people worldwide are projected to have AMD by 2040, as the world’s population is growing older and it is a disease that disproportionately affects elder individuals [2, 3]. AMD encompasses two main subtypes: non-neovascular AMD and nAMD. While the non-neovascular form accounts for the majority of cases, nAMD is responsible for approximately 80% of severe vision loss associated with AMD [4]. nAMD is characterized by the growth of pathologic choroidal neovascular membranes (CNVM) which lead to haemorrhage and exudation in the retina. This abnormal vascular growth is driven by the upregulation of VEGF, a growth factor involved in angiogenesis and vascular permeability [5].
The introduction of intravitreally administered anti-VEGF agents marked a significant breakthrough in the treatment of nAMD. Previous treatments, including photodynamic therapy with verteporfin, intravitreal steroids, focal laser therapy, and surgical excision of CNVMs, did not improve vision and grew obsolete [6]. Pegaptanib (Macugen, Pfizer) was the first FDA-approved anti-VEGF agent in 2004, however, with the introduction of other increasingly effective anti-VEGF therapies, the utilization of this drug has significantly diminished. Today, the most commonly used agents to treat nAMD include bevacizumab, ranibizumab, aflibercept, brolucizumab, and faricimab (Table 1). Brolucizumab (Beovu, Novartis) was FDA-approved to treat nAMD in 2019 but recent concerns regarding related retinal vasculitis and intraocular inflammation have raised caution around its use [7]. Faricimab (Vabysmo, Roche/Genentech) was most recently approved in 2022 and is the only agent which targets both VEGF-A and angiopoietin-2 (Ang-2).
However, despite these advancements, the current standard of care presents practical limitations, including high treatment costs, the need for frequent intravitreal injections, intravitreal-injection related fear and anxiety, and transportation issues [8, 9]. These factors hinder adherence to treatment regimens leading to a 2-year loss to follow-up rate of 28% and a 5-year loss to follow-up rate of 57% [10, 11]. Additionally, there are concerns related to treatment response, such as non-responders and the development of adverse outcomes like fibrosis, which impact visual improvement [12]. For example, in the MARINA and ANCHOR clinical trials, approximately 10% of patients treated with ranibizumab experienced a decrease in visual acuity of 15 letters or more from baseline, highlighting the variability in patient response to anti-VEGF therapy [13]. The limitations of current nAMD therapies have prompted a growing interest in the development of novel agents and treatment modalities. Researchers are exploring alternative pathways and targeting molecules beyond VEGF to improve outcomes and reduce the burden of frequent injections. This review article will explore the current therapeutic landscape of nAMD by describing ongoing clinical trials and emerging therapies, including gene therapy, combination anti-VEGF agents, and novel mechanisms of action.
Methods
Therapeutics included in this review were identified through a search of ClinicalTrials.gov with the search terms “Neovascular Age-Related Macular Degeneration” and “Wet Age-related Macular Degeneration.” Inclusion criteria include: therapeutics with novel mechanisms of action to nAMD treatment in phase 1–3 clinical trials. Exclusion criteria include: no clinical trial results, sustained delivery systems of existing therapeutics, therapeutics exclusively targeting complement, and anti-VEGF biosimilars. Data was obtained in January 2024.
Gene therapy
RGX-314 (REGENXBIO, Rockville, Maryland) is a promising gene therapy for nAMD that utilizes an adeno-associated virus serotype 8 (AAV8) vector expressing a ranibizumab like anti-VEGF Fab (Table 2). A phase I/IIa open-label dose-escalation study (n = 42), compared five cohorts receiving escalating doses of subretinal RGX-314. RGX-314 was found to be generally well–tolerated across all dose levels with one possible drug-related serious adverse event (SAE) of significantly decreased visual acuity in a patient in the highest dose cohort [14, 15]. Patients receiving the second highest and highest dose level in this study experienced a 58.3% and 81.2% reduction in anti-VEGF injection rate over 1.5 years, respectively [14]. Interim data from the phase II AAVIATE® trial (NCT04514653) utilizing a suprachoroidal delivery method demonstrates that RGX-314 continues to be well tolerated among the 106 patients enroled in its three dose levels with no drug-related SAEs [16]. At the highest dose level, 50% of patients remain injection-free after RGX-314 administration and experience an overall 80% reduction in injection rate each year, while maintaining a stable best-corrected visual acuity (BCVA). Ongoing trials, ATMOSPHERE® (phase IIb/III, NCT04704921) and ASCENT® (phase III, NCT05407636), are further evaluating subretinal delivery of RGX-314.
Ixoberogene soroparvovec (Ixo-vec) (Adverum Biotechnologies, Redwood City, California), previously known as ADVM-022, features an intravitreally (IVT) injected proprietary vector capsid, AAV.7m8, carrying a ubiquitous expression cassette encoding the aflibercept protein [17]. In the OPTIC phase I trial (NCT03748784), Ixo-vec demonstrated an acceptable safety profile with the most common drug-related adverse event being ocular inflammation (60%; n = 18) which responded well to topical corticosteroids [18, 19]. Key data from OPTIC revealed sustained aqueous humour levels of aflibercept over 96 weeks, leading to a reduction in the annualized anti-VEGF injection rate of 81% in the low-dose group and 98% in the high-dose group [18]. By 2 years, 53% of patients in the low-dose group and 80% in the high-dose group remained free from additional anti-VEGF injections. The phase II LUNA trial (NCT05536973) assessing Ixo-vec’s safety and efficacy is currently active, but not yet recruiting with an enrolment goal of 72 patients.
4D-150 (4D Molecular Therapeutics (4DMT), Emeryville, California) utilizes a proprietary AAV vector, R100, which can infiltrate the internal limiting membrane to increase retinal transgene expression. The vector carries a transgene cassette that expresses both aflibercept and a VEGF-C inhibitory miRNA, effectively inhibiting VEGF A, B, C, and placental growth factor. Interim results from its phase I/II trial, PRISM (NCT05197270), demonstrate 4D-150’s safety with no drug-related SAEs or dose-limiting toxicities [20]. At 36 weeks, 80% of participants did not require additional supplemental anti-VEGF injections with a 97.6% decline in the annualized anti-VEGF injection rate [20]. The FDA recently granted 4D-150 Regenerative Medicine Advanced Therapy designation, a first for any nAMD targeted therapy [21]. Collaborating with both the FDA and EMA, 4DMT is now working on preliminary phase III clinical trial plans.
Anti-VEGF related
OPT-302 (Opthea limited, Victoria Australia) is a novel recombinant fusion “trap” protein consisting of three extracellular ligand-binding domains of human VEGF receptor(VEGFR)-3 fused to the constant domain of human immunoglobulin G1 (Table 2) [22, 23]. It specifically binds to and sequesters VEGF-C and VEGF-D, preventing their binding to VEGFR-2 and VEGFR-3 [22]. Intended to be administered via IVT injection along with traditional anti-VEGF agents that selectively target VEGF-A, a phase IIb dose-ranging study (NCT03345082) found that 2.0 mg OPT-302 in addition to ranibizumab generated substantial increases in visual acuity compared to ranibizumab alone [22]. OPT-302 produced anatomic improvements (a decrease in central subfield thickness (CST) of 14 μm and 12.9 μm in 0.5 mg and 2 mg groups, respectively) when compared with sham and was also found to have a favourable safety profile, with no significant differences across groups [22]. OPT-302 is currently undergoing phase III trials, building upon the promising phase IIb results. The ShORe (NCT04757610) and COAST (NCT04757636) trials aim to further assess the efficacy and safety of OPT-302 along with ranibizumab and aflibercept, respectively.
BI 836880 (Boehringer Ingelheim, Germany) is an IVT delivered humanized bispecific nanobody® designed to strongly bind to and inhibit the activity of VEGF-A and Ang-2 [24]. An additional albumin molecule is present on the nanobody, which extends its half-life post-injection [25]. A phase I/IIa trial (NCT03861234) revealed no drug-related or dose-limiting adverse events and demonstrated preliminary signs of efficacy in the improvement of BCVA [26]. Further investigations to explore the potential of BI 836880 are not yet active.
Tarcocimab tedromer (KSI-301) (Kodiak Sciences Inc., Palo Alto, California) is an IgG1 anti-VEGF antibody biopolymer conjugate targeting all VEGF-A isoforms, administered via IVT injection [27]. The DAYLIGHT phase III clinical trial (NCT04964089) demonstrated that monthly injections of Tarcocimab tedromer resulted in non-inferior improvements in BCVA at one year compared to aflibercept (3.9 vs. 5.5 ETDRS letters), with a similar decrease in CST (117 μm vs. 109 μm) [27]. Its safety profile was favourable, exhibiting low rates of intraocular inflammation (3.3%, n = 276) and no cases of intraocular inflammation with vasculitis or vascular occlusion. Tarcocimab tedromer will be further investigated in the DAYBREAK trial, which has an enrolment target of mid-2024.
Tyrosine kinase inhibitor
EYP-1901 (EyePoint Pharmaceuticals, Watertown, Massachusetts) combines EyePoint’s proprietary bioerodible Durasert® delivery technology with vorolanib, a selective tyrosine kinase inhibitor, which is a potent pan-VEGFR and platelet-derived growth factor receptor inhibitor (Table 2) [28]. In the phase I DAVIO trial (NCT04747197), EYP-1901 demonstrated positive twelve-month safety data with no reports of drug-related ocular or systemic SAEs and no dose-limiting toxicities [29]. The trial showed that after one dose 53% of patients did not need rescue anti-VEGF injections at 6 months [29]. Interim data from the phase II DAVIO 2 trial (NCT05381948) indicate that it met its primary endpoint, with both of the EYP-1901 doses utilized demonstrating non-inferiority in the change in BCVA compared to the aflibercept control [30]. The trial also achieved key secondary endpoints, including an over 80% reduction in anti-VEGF injection rate and almost two-thirds of patients not requiring additional anti-VEGF injections for up to six months [30].
OTX-TKI (Ocular Therapeutix, Bedford, Massachusetts) is an intravitreal bioresorbable hydrogel implant incorporating axitinib, a small molecule tyrosine kinase inhibitor. Axitinib is a selective and potent inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3 and is currently FDA approved for the treatment of advanced renal cell carcinoma [31]. The hydrogel implant maintains therapeutic levels of axitinib, which is slowly diffused through the hydrogel network. The current phase I trial (NCT04989699) has produced positive 12-month results. OTX-TKI sustained visual acuity at levels similar to those achieved with aflibercept administered every eight weeks, resulting in an 89% reduction in anti-VEGF injection rate [32]. The therapeutic showed no drug-related ocular nor systemic SAEs [32]. Additionally, the observed consistent bioresorption of the implant at around nine months in the trial provides valuable insights into a potential redosing timeline. A phase III trial with an enrolment goal of 300 patients is set to begin shortly.
CLS-AX (Clearside Biomedical, Inc.) utilizes a proprietary suprachoroidal space microinjector to deliver a suspension of axitinib. The phase I OASIS trial (NCT04626128) and its 12-week extension study demonstrated an excellent safety profile in all dose cohorts with no SAEs and no adverse events from inflammation [33]. Through the extension study, the trial resulted in a 77% decrease in treatment burden with 50% of patients not requiring additional therapy at 6 months and stable BCVAs and CSTs [33]. A phase IIb clinical trial, ODYSSEY (NCT05891548), is currently active comparing CLS-AX with Faricimab, with topline data anticipated in the third quarter of 2024.
KHK4951 (Tivozanib) (Kyowa Kirin Co., Ltd.) is a small-molecule tyrosine kinase inhibitor targeting VEGFR-1, -2, and -3 [34]. Tivozanib is currently FDA approved for the treatment of relapsed or refractory advanced renal cell carcinoma. In this formulation it is administered as an eye drop and features nano-crystallized tivozanib, designed for efficient delivery to posterior ocular tissues. In a phase I clinical trial (NCT04594681), the therapeutic successfully met its safety outcome with a minimal number of adverse events. Currently, a phase II trial (NCT06116890) is actively recruiting patients to further evaluate its efficacy and safety.
Additional targets
UBX1325 (Unity Biotechnology, South San Francisco, California) is a small molecule inhibitor of Bcl-xL, an anti-apoptotic protein within the Bcl-2 family (Table 2) [35]. It promotes apoptosis of senescent vascular endothelial cells which secrete VEGF, thereby exhibiting anti-VEGF properties [36]. While its phase II ENVISION study (NCT05275205) exhibited a favourable safety and tolerability profile, UBX1325 did not meet the non-inferiority margin at 24 weeks compared to aflibercept [35, 37]. Despite this, 52% of treated participants did not require a supplemental anti-VEGF injection at 24 weeks [37]. Further exploration of UBX1325 is being conducted in diabetic macular oedema, with a phase IIb trial (NCT06011798) actively recruiting.
Restoret (EYE103) (Eyebiotech Limited, United Kingdom) is a tri-specific Wnt agonist antibody delivered by IVT injection. Restoret mimics the natural ligand Norrin, which agonizes the Wnt signalling pathway [5, 38]. Norrin is crucial in restoring and maintaining the blood-retinal barrier by inducing tight junction organization, limiting vascular permeability [5, 39]. The phase Ib/IIa AMARONE (Anti-permeability Mechanism and Age-Related Ocular Neovascularization Evaluation) clinical trial (NCT05919693) is a two-part study, comprising an open-label multiple ascending dose safety study and a dose-finding single-masked comparative safety and preliminary efficacy study of IVT Restoret. Preliminary 12-week data from this study revealed no drug-related SAEs and that Restoret was well tolerated [38]. Eyebiotech Limited also reported an increase in BCVA of +11.2 letters and a decrease in retinal thickness of 143 microns among patients in the diabetic macular oedema arm of the study (n = 26) with similar results in those in the nAMD arm (n = 5) who received combination therapy with aflibercept [38].
Conclusion
In conclusion, nAMD continues to present a substantial global health challenge with a growing prevalence projected for the future. The advent of IVT administered anti-VEGF agents marked a breakthrough, significantly improving outcomes compared to previous modalities. However, the current standard of care for nAMD poses the previously mentioned practical limitations and efficacy issues.
The pursuit of therapies that address the multifaceted challenges of nAMD remains crucial. The development of longer-lasting drugs, gene therapy, and alternative pathways reflects a shift towards enhancing patient satisfaction and compliance and reducing the overall management burden associated with nAMD. While the investigational landscape for nAMD is promising (Table 2), it is essential to acknowledge the high standard set by current anti-VEGF therapies. Future advancements should aim not only for equivalent or superior efficacy but also for improved safety, tolerability, and convenience. The complexity of nAMD pathogenesis demands a multifaceted approach, and ongoing research holds the potential to redefine the treatment paradigm for this visually debilitating condition.
References
Quartilho A, Simkiss P, Zekite A, Xing W, Wormald R, Bunce C. Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013. Eye Lond Engl. 2016;30:602–7.
Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–116.
Klein R, Klein BEK, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-Year Cumulative Incidence of Age-Related Macular Degeneration: The Beaver Dam Eye Study. Ophthalmology. 2007;114:253–62.
Ferris FL, Fine SL, Hyman L. Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy. Arch Ophthalmol. 1984;102:1640–2.
Chidiac R, Abedin MD, Macleod G, Yang A, Thibeault PE, Blazer LL, et al. A Norrin/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathy. EMBO Mol Med. 2021;13:e13977.
Smith AG, Kaiser PK. Emerging treatments for wet age-related macular degeneration. Expert Opin Emerg Drugs. 2014;19:157–64.
Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, et al. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology. 2020;127:1345–59.
Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23:127–40.
Droege KM, Muether PS, Hermann MM, Caramoy A, Viebahn U, Kirchhof B, et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2013;251:1281–4.
Barthelmes D, Nguyen V, Daien V, Campain A, Walton R, Guymer R, et al. TWO YEAR Outcomes Of “TREAT AND EXTEND” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. RETINA. 2018;38:20.
Boulanger-Scemama E, Querques G, About F, Puche N, Srour M, Mane V, et al. Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol. 2015;38:620–7.
Mettu PS, Allingham MJ, Cousins SW. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82:100906.
Tsilimbaris MK, López-Gálvez MI, Gallego-Pinazo R, Margaron P, Lambrou GN. Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD. J Ophthalmol. 2016;2016:4367631.
REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD. Regenxbio Inc. 2021. Available from: https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-additional-positive-interim-phase-iiia-and/.
REGENXBIO Inc. A Phase I/IIa (Phase 1/Phase 2a), Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD). clinicaltrials.gov; 2023. Report No.: NCT03066258. Available from: https://clinicaltrials.gov/study/NCT03066258.
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery. Regenxbio Inc. Available from: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-positive-interim-data-phase-ii-aaviater/.
Grishanin R, Vuillemenot B, Sharma P, Keravala A, Greengard J, Gelfman C, et al. Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration. Mol Ther. 2019;27:118–29.
Khanani AM, Boyer DS, Wykoff CC, Regillo CD, Busbee BG, Pieramici D, et al. Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study. eClinicalMedicine. 2024;67. Available from: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00571-0/fulltext#secsectitle0115.
Poulsen K, Hanna K, Schaefer-Swale K, Nieves J, Engbers C, Nguyen N, et al. Ixoberogene soroparvovec (Ixo-vec) for the treatment of neovascular age-related macular degeneration: Nonclinical data in support of human equivalent dose of 6E10 vg/eye and staggered bilateral dosing. Invest Ophthalmol Vis Sci. 2023;64:460.
Khanani AM, Hershberger VS, Kay CN, Hu A, Eichenbaum DA, Jaffe GJ, et al. Interim results for the Phase 1/2 PRISM Trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration. Invest Ophthalmol Vis Sci. 2023;64:5055.
Ophthalmology Times. 4DMT receives FDA Regenerative Medicine Advanced Therapy designation for 4D-150 genetic medicine for intravitreal treatment of Wet AMD. 2023. Available from: https://www.ophthalmologytimes.com/view/4dmt-receives-fda-regenerative-medicine-advanced-therapy-designation-for-4d-150-genetic-medicine-for-intravitreal-treatment-of-wet-amd.
Jackson TL, Slakter J, Buyse M, Wang K, Dugel PU, Wykoff CC, et al. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2023;130:588–97.
Tolentino MJ, Tolentino AJ. Investigational drugs in clinical trials for macular degeneration. Expert Opin Investig Drugs. 2022;31:1067–85.
Le Tourneau C, Becker H, Claus R, Elez E, Ricci F, Fritsch R, et al. Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. ESMO Open. 2022;7:100576.
Hofmann I, Baum A, Hilberg F, Garin Chesa P, Depla E, Boucneau J, Kraut N, et al. Dual targeting of angiogenesis pathways: combined blockade of VEGF and Ang2 signaling. In: 8th Euro Global Summit on Cancer Therapy. Valencia, Spain; 2015.
Zeitz O, Edwards A, Hu A, Berger B, Simons G, ehrlich michael, et al. Phase I/IIa study examining the safety and tolerability of single and multiple rising intravitreal doses of BI 836880 in patients with wAMD. Invest Ophthalmol Vis Sci. 2022;63:3124.
Busbee B. Tarcocimab tedromer (KSI-301) 5 mg for the treatment of wAMD: One-year primary efficacy and safety outcomes of the Phase 3 DAYLIGHT Study. In: 56th Annual Scientific Meeting of the Retina Society. New York, NY; 2023.
Gao Y, Lu F, Li X, Dai H, Liu K, Liu X, et al. Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study. Eye. 2023;37:3228–33.
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD. EyePoint Pharmaceuticals. 2022. Available from: https://investors.eyepointpharma.com/news-releases/news-release-details/eyepoint-pharmaceuticals-announces-first-patient-dosed-phase-2.
EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints. EYPT Stock News. 2023. Available from: https://www.stocktitan.net/news/EYPT/eye-point-pharmaceuticals-announces-positive-topline-data-from-the-rg296pcjej3m.html.
Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clin Cancer Res. 2008;14:7272–83.
Avery LR. OTX-TKI, Sustained-Release Axitinib Hydrogel Implant, for Neovascular AgeRelated Macular Degeneration. In: 56th Annual Scientific Meeting of the Retina Society. New York, NY; 2023.
Kuppermann BD. Safety and Tolerability Study of Suprachoroidal Injections of CLS-AX in Neovascular AMD Patients with Persistent Activity Following Anti-VEGF Therapy: OASIS Phase 1/2a Clinical Trial 6-Month Extension Study Results. In: The Macula Society 46th Annual Meeting; 2023; Miami Beach, Florida. Available from: https://clearsidebio.com/wp-content/uploads/2023/02/Macula-Society-2023-Kuppermann.pdf.
Kyowa Kirin US. Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema. 2024. Available from: https://www.kkna.kyowakirin.com/media-center/kyowa-kirin-announces-first-patient-enrolled-in-the-phase-2-clinical-trial-evaluating-tivozanib-eye-drops-in-patients-with-diabetic-macular-edema/.
Hassan JW, Bhatwadekar AD. Senolytics in the treatment of diabetic retinopathy. Front Pharm. 2022;13:896907.
Jones A. A Look At Unity’s UBX1325 Phase 1 Results (NASDAQ:UBX). Seeking Alpha. 2021. Available from: https://seekingalpha.com/article/4441467-a-look-at-unitys-ubx1325-phase-1-results.
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration. Unity Biotechnology. 2023. Available from: https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-announces-results-phase-2-envision-study/.
BioSpace. EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of RestoretTM in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema. 2023. Available from: https://www.biospace.com/article/eyebio-announces-first-patients-dosed-in-phase-1b-2-trial-of-restoret-in-neovascular-age-related-macular-degeneration-and-diabetic-macular-edema/.
Díaz-Coránguez M, Lin CM, Liebner S, Antonetti DA. Norrin restores blood-retinal barrier properties after vascular endothelial growth factor–induced permeability. J Biol Chem. 2020;295:4647–60.
Acknowledgements
RPS reports personal fees from Appelis, Iveric Bio, Eyepoint, Regenxbio, Genentech, Bausch and Lomb, Zeiss, Alcon, and Regeneron, and research grants from Jannsen. All other authors report no disclosures.
Funding
This work was supported by the Research to Prevent Blindness (RPB) Challenge Grant, Cleveland Eye Bank Foundation Grant P30EY025585(BA-A).
Author information
Authors and Affiliations
Contributions
All authors were responsible for the study conception and design, drafting, and revisions. JDS and PS were responsible for data analysis and interpretation. JDS was responsible for data extraction. All authors approved the final manuscript and agreed to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Shirian, J.D., Shukla, P. & Singh, R.P. Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues. Eye 39, 40–44 (2025). https://doi.org/10.1038/s41433-024-03373-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41433-024-03373-x